DocuSign (DOCU) reported Q4 profits that surpassed expectations with an EPS of $1.01, while Piper Sandler maintained a 'Neutral' rating on the stock.

RBC has expressed caution regarding DocuSign (DOCU) following the release of the company's fourth-quarter financial results.

UBS analysts have reduced their price target for DocuSign (DOCU) stock, with reasons for the adjustment provided.

Analysts are offering their insights and perspectives on the performance and outlook of technology companies including Micron, DocuSign, and IBM, with specific advice on whether to 'buy the dip' on Micron.

An analysis explores the factors that make Docusign (DOCU) an attractive company.